Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Operating Margin (2022 - 2025)

Taysha Gene Therapies' Operating Margin history spans 4 years, with the latest figure at 1347.08% for Q2 2025.

  • For Q2 2025, Operating Margin rose 56830.0% year-over-year to 1347.08%; the TTM value through Sep 2025 reached 1618.54%, down 73329.0%, while the annual FY2024 figure was 1097.55%, 62872.0% down from the prior year.
  • Operating Margin for Q2 2025 was 1347.08% at Taysha Gene Therapies, down from 930.54% in the prior quarter.
  • Across five years, Operating Margin topped out at 7388.54% in Q1 2022 and bottomed at 1915.38% in Q2 2024.
  • The 4-year median for Operating Margin is 582.03% (2023), against an average of 536.69%.
  • The largest annual shift saw Operating Margin tumbled -774041bps in 2023 before it soared 56830bps in 2025.
  • A 4-year view of Operating Margin shows it stood at 4135.33% in 2022, then plummeted by -111bps to 450.78% in 2023, then plummeted by -119bps to 985.76% in 2024, then plummeted by -37bps to 1347.08% in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Operating Margin are 1347.08% (Q2 2025), 930.54% (Q1 2025), and 985.76% (Q4 2024).